---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-115027"
form_type: "8-K"
ticker: null
cik: "0001888012"
company_name: "HilleVax, Inc."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T14:06:34.143193+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HilleVax cuts 15 employees (25% of workforce) to reduce costs; exploring strategic alternatives

## Summary
- Workforce reduction of approximately 15 employees (~25% of total workforce).
- Estimated charges of ~$1.3M for severance, benefits and termination costs, expected in Q4 2024.
- Company exploring continued development of norovirus vaccine candidates and business development/strategic alternatives.
- Action aims to reduce operating expenses amid uncertainty over lead candidate HIL-214.

## SEC filing metadata
- accession: 0000950170-24-115027
- form_type: 8-K
- cik: 0001888012
- company_name: HilleVax, Inc.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888012/000095017024115027/0000950170-24-115027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888012/000095017024115027/hlvx-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-115027
- JSON: https://secwatch.observer/filing/0000950170-24-115027.json
- Plain text: https://secwatch.observer/filing/0000950170-24-115027.txt

## Key facts
- Restructurings & Charges
  HilleVax, Inc. announced a restructuring with charges of approximately $1.3 million (approximately 15 employees, constituting approximately 25% of the Company's workforce).
  - Type: restructuring
  - Charge: approximately $1.3 million
  - Headcount: approximately 15 employees, constituting approximately 25% of the Company's workforce
  source text: these vaccine candidates and other strategic alternatives. The Company currently estimates that it will incur charges associated with the workforce reduction of approximately $1.3 million primarily related to employee severance payments, benefits and related termination costs. The Company expects that the reduction in force will be substantially complete with the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888012/000095017024115027/0000950170-24-115027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.